Action 300497 JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Jiangxi Fushine Pharmaceutical Co., Ltd.

Actions

300497

CNE1000024Z7

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 25/04/2024 		Varia. 5j. Varia. 1 janv.
9,02 CNY +4,28 % Graphique intraday de Jiangxi Fushine Pharmaceutical Co., Ltd. +10,54 % -3,63 %
19/02 L'unité de Fushine Pharma obtient le feu vert pour le tazobactam sodique MT
2023 L'unité de Fushine Pharmaceutical reçoit le feu vert pour commercialiser un antidépresseur MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Fushine Pharma's Unit Gets Nod for Tazobactam Sodium
Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding
Fushine Pharmaceutical's Unit Gets Nod to Market Antidepressant
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Jiangxi Fuxiang Pharma to Invest 32.5 Million Yuan in New Biotechnology Unit
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Fuxiang Pharma's Profit to Rise in H1
Fuxiang Pharma’s Vice Chairman, Deputy General Manager to Boost Shareholding
Fushine Pharma Earmarks 386 Million Yuan to Build New Chemical Factory
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.
Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 4, 2021, has expired with 11,355,900 shares, representing 2.09% for CNY 174.83 million.
LinkChem Co., Ltd. announced that it has received CNY 117 million in funding from Jiangxi Fushine Pharmaceutical Co., Ltd.
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
LinkChem Co., Ltd. announced that it expects to receive CNY 117 million in funding from Jiangxi Fushine Pharmaceutical Co., Ltd.
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 300497
  4. Actualités Jiangxi Fushine Pharmaceutical Co., Ltd.
  5. Autres langues